Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases.
Budd Chiari Syndrome
COVID-19
Portosinusoidal Vascular Disease
SARS-CoV-2
Splanchnic Vein Thrombosis
Vascular Liver Diseases
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
13
10
2021
revised:
14
12
2021
accepted:
16
12
2021
pubmed:
31
12
2021
medline:
22
6
2022
entrez:
30
12
2021
Statut:
ppublish
Résumé
Vascular liver diseases (VLDs) are represented mainly by portosinusoidal vascular disease (PSVD), noncirrhotic splanchnic vein thrombosis (SVT), and Budd Chiari syndrome (BCS). It is unknown whether patients with VLDs constitute a high-risk population for complications and greater coronavirus disease 2019 (COVID-19)-related mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLDs, as well as to assess its impact on hepatic decompensation and survival. This is an observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLDs between March 2020 and March 2021, compared with the general population (GP). Patients from Spain (5 centers; n = 493) and France (1 center; n = 475) were included. Nine hundred sixty-eight patients were included: 274 with PSVD, 539 with SVT, and 155 with BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 with PSVD, 77 with SVT, and 8 with BCS. The prevalence of SARS-CoV-2 infection in patients with PSVD (19%) and SVT (14%) was significantly higher than in the GP (6.5%; P < .05), whereas it was very similar in patients with BCS (5%). In terms of infection severity, patients with VLDs also presented a higher need of hospital admission (14% vs 7.3%; P < .01), intensive care unit admission (2% vs 0.7%; P < .01), and mortality (4% vs 1.5%; P < .05) than the GP. Previous history of ascites (50% vs 8%; P < .05) and post-COVID-19 hepatic decompensation (50% vs 4%; P < .05) were associated with COVID-19 mortality. Patients with PSVD and SVT could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease.
Sections du résumé
BACKGROUND & AIMS
Vascular liver diseases (VLDs) are represented mainly by portosinusoidal vascular disease (PSVD), noncirrhotic splanchnic vein thrombosis (SVT), and Budd Chiari syndrome (BCS). It is unknown whether patients with VLDs constitute a high-risk population for complications and greater coronavirus disease 2019 (COVID-19)-related mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLDs, as well as to assess its impact on hepatic decompensation and survival.
METHODS
This is an observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLDs between March 2020 and March 2021, compared with the general population (GP). Patients from Spain (5 centers; n = 493) and France (1 center; n = 475) were included.
RESULTS
Nine hundred sixty-eight patients were included: 274 with PSVD, 539 with SVT, and 155 with BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 with PSVD, 77 with SVT, and 8 with BCS. The prevalence of SARS-CoV-2 infection in patients with PSVD (19%) and SVT (14%) was significantly higher than in the GP (6.5%; P < .05), whereas it was very similar in patients with BCS (5%). In terms of infection severity, patients with VLDs also presented a higher need of hospital admission (14% vs 7.3%; P < .01), intensive care unit admission (2% vs 0.7%; P < .01), and mortality (4% vs 1.5%; P < .05) than the GP. Previous history of ascites (50% vs 8%; P < .05) and post-COVID-19 hepatic decompensation (50% vs 4%; P < .05) were associated with COVID-19 mortality.
CONCLUSIONS
Patients with PSVD and SVT could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease.
Identifiants
pubmed: 34968728
pii: S1542-3565(21)01356-2
doi: 10.1016/j.cgh.2021.12.032
pmc: PMC8710430
pii:
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1525-1533.e5Informations de copyright
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Thromb Haemost. 2020 Jun;120(6):998-1000
pubmed: 32316063
J Hepatol. 2021 Mar;74(3):567-577
pubmed: 33035628
Dig Liver Dis. 2021 Aug;53(8):937-949
pubmed: 34120860
J Hepatol. 2020 Nov;73(5):1231-1240
pubmed: 32553666
Hepatology. 2018 Dec;68(6):2413-2423
pubmed: 30066417
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
PLoS One. 2021 Mar 3;16(3):e0247251
pubmed: 33657157
Nat Rev Gastroenterol Hepatol. 2021 May;18(5):348-364
pubmed: 33692570
J Hepatol. 2021 Jun;74(6):1335-1343
pubmed: 33508378
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Virchows Arch. 2018 Jul;473(1):3-13
pubmed: 29572606
J Hepatol. 2019 Jul;71(1):175-199
pubmed: 30822449
Gastroenterology. 2020 Jul;159(1):320-334.e27
pubmed: 32407808
United European Gastroenterol J. 2021 Mar;9(2):159-176
pubmed: 33210980